A Review on Covid-19 Pandemic a Global Threat-Current Status and Challenges and Preventive Strategies

Objective: A novel coronavirus infection (SARS-CoV-2) pneumonia (COVID-19) has been quickly spreading throughout China and the rest of the world since December 2019. Respiratory tract infections are frequently linked to diabetes mellitus (DM), a different risk factor. This study has reported the clinical presentation and therapeutic outcomes of COVID-19 with diabetes. Methods: From medical records and histories provided by 72 Covid-19-infected patients with diabetes admitted to the KMCH institute of health sciences and research, Coimbatore, data on demographics, clinical, laboratory, and radiological characteristics as well as treatment outcomes were collected using data collection forms. Real-time reverse transcription polymerase chain reaction (RT-PCR) assay of 2019-CoV RNA was used to screen patients with Covid-19. Results: 72 diabetes patients who tested positive for Covid-19 were admitted for this study. SPSS software version 26 was used to evaluate the data that had been collected. Clinical profiles and outcomes of patients with and without diabetes underwent descriptive analysis. Controlled diabetics had a mean plasma glucose of 112.22±11.41, while uncontrolled diabetics had a mean plasma glucose of 154.2±23.22. Fever was the most prevalent symptom in both managed and uncontrolled diabetes patients (94% and 100%), followed by sore throat (84% and 88%). In patients with uncontrolled diabetes compared to those with controlled diabetes, breathlessness is considerably higher (p<0.05). In the CORADS scoring, 11 of the 34 diabetics with uncontrolled blood sugar levels had CORADS 6 (32.35%), compared to just 2 of the 38 diabetics with regulated blood sugar levels (5.26%), which is considerably higher (p<0.01). In uncontrolled diabetics, the length of hospital stay is much longer (p<0.001). Compared to diabetics with controlled blood sugar, uncontrolled patients SPO2 dramatically dropped (p<0.001). Those with uncontrolled diabetes are more likely to be admitted to the ICU than patients with controlled diabetes (p<0.05). In uncontrolled diabetes compared to controlled patients, the severity was considerably higher (p<0.05). One person who had uncontrolled diabetes died, although no one who had controlled diabetes died. Conclusion: Covid 19, persons with uncontrolled diabetes appear to be more likely to sustain lung damage, necessitating admission to the ICU, an extended stay in the hospital, and oxygen assistance throughout the duration of the illness.

Section: Introductionmentioning

confidence: 99%

Impact of Diabetes Mellitus on Clinical Profile and Outcome of Covid-19 Patients in a Tertiary Care Hospital

SRIDHAR²,

Bhuvaneshwari

et al. 2023

“…COVID-19 (coronavirus disease 2019) appeared from Wuhan city of China, in late December 2019. According to the world health organization (WHO), COVID-19 was considered a pandemic on 11 March 2020 [1,2]. COVID-19 is caused by the coronavirus-novel RNA virus because it is a new strain that has not been previously identified in humans.…”

Section: Introductionmentioning

confidence: 99%

The Impact of Covid-19 Pandemic on Various Stress Factors and Its Correlation With Hair Fall: An Online-Based Survey Among Bangladeshi Residents

SHAHED,

TASNEEM,

SULTANA

et al. 2023

Objective: The COVID-19 pandemic has triggered several stress factors throughout the entire world. Some stress factors, such as mental, economical, educational etc., have created consequences like hair fall, as seen in individuals in many countries, including Bangladesh. The present study was designed to investigate the covid-19-induced stress factors and their relation with hair loss in the people of Bangladesh. Methods: An online-based survey study was carried out using a self-made questionnaire, and quantitative data were analyzed by a cross-sectional analysis over the period of two months from November 25, 2020, to January 24, 2021. Participants who were willing to participate into this survey were considered as study individuals. This survey was conducted among participants with age’s ≥18 y. The participants were selected by snowball sampling technique, and the final collected sample size was 808. Results: Among 808 participants, males and females were 50.3% (406) and 49.7% (402), respectively. We found that 5% (37) participants were infected with Covid-19, 89% (715) were not infected, and 7% (56) were unknown. It is found that COVID-19-induced stress conditions including educational 28%, mental 25%, and economical 20% were found in 81% (655) participants and rendered 68% (550) people facing the hair fall problem due to COVID-19-related stress. Female individuals who were more stressed were 74.6% (300) and had hair fall, whereas males were 38.7% (157). In addition, the increased rate of hair fall in COVID-19 is associated with other factors, such as eating disorders and scalp infections, as reported by some respondents. Conclusion: In pandemic situations, most of the people (81%) passed through the stressful condition, and the females experienced more hair fall problems than male one. High blood pressure, eating disorder and irregular sleep pattern are considered stress-induced factors that were responsible for increased hair loss.

“…Pangolin-CoV was hypothesized to be the second closest relative of SARS-CoV-2 (91.02% whole genome level) [3,4]. Poor proofreading capability of the viral RNA polymerase and homologous recombination between CoVs might be the probable reasons of fast mutational frequency that might contribute to "cross-species" transmission [5,6]. COVID 19 genome consisted of single-stranded RNA composed of about 30 kb nucleotides, 5'untranslated region (UTR), a replicase complex (orf1ab) encoding non-structural proteins (nsps), a spike protein (S) gene, envelope protein (E) gene, a membrane protein (M) gene, a nucleocapsid protein (N) gene, 3'-UTR, and several unidentified non-structural open reading frames [7,8].…”

Section: Introductionmentioning

confidence: 99%

Comprehensive Therapeutic Interventions Against Sars-Cov-2: A Review and Prospective

PRASAD

2022

In December 2019, Wuhan City, Hubei Province, China, first reported pneumonia like symptoms with unknown aetiology caused by a novel coronavirus. The novel coronavirus was renamed as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Coronaviridae Study Group of the International Committee on Taxonomy of Viruses and the disease was termed as Coronavirus Disease 2019 (COVID-19). As of 19 August, 2022, the infection has reached above 220 countries, areas or territories with a total of 591 683 619 confirmed cases and 6 443 306 deaths, as published by the World Health Organization (WHO). SARS-CoV-2 is strongly contagious as it has R0, 2.2-2.6, in comparison to SARS-CoV (<1) and Middle East respiratory syndrome coronavirus (MERS-CoV) (1.4-2.5), respectively. SARS-CoV-2 might become less virulent than the SARS-CoV and MERS-CoV, with the currently analyzed mortality of COVID-19 is 3.4%. The original SARS-CoV-2 has undergone “virus evolution” with the occurrence of numerous variants such as Alpha, Beta, Gamma and Delta etc. Recently, the circulating variant of concern is Omicron subvariants. Currently, real-time reverse transcription–polymerase chain reaction-based detection of the viral genome (RNA) is the gold standard for diagnosis of SARS-CoV-2 infection. At present, Remdesivir (RDV) and Baricitinib drugs as well as vaccines Pfizer-BioNTech and Moderna have been approved for the treatment of COVID-19 by Food and Drug Administration (FDA). In this review, we summarized the existing state of knowledge on approved antiviral therapy, combination therapy, blood-derived therapeutics and immunomodulators to treat COVID-19 pandemic.